DOT1L and non-small cell lung carcinoma: Specific DOT1L inhibitors like EPZ5676, EPZ004777, and SGC0946, as well as over 20 other small molecule inhibitors, have shown significant inhibitory effects on NSCLC cells with the DOT1L R231Q mutation when combined with chemotherapy drugs (117).